2024 Nasdaq rxrx - Today, we take our first look at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX). The stock is now deep in Busted IPO territory. Do the shares merit that fate or is something better ahead?

 
Lexicon Pharmaceuticals, Inc. Common Stock (LXRX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.. Nasdaq rxrx

Rhumbline Advisers grew its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 22.9% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC).The fund owned 257,975 shares of the company’s stock after purchasing an additional …Oct 11, 2022 · Recursion Pharmaceuticals has a market capitalisation of US$1.9b and burnt through US$113m last year, which is 6.0% of the company's market value. Given that is a rather small percentage, it would ... Webull offers RXRX Ent Holdg (RXRX) historical stock prices, in-depth market analysis, NASDAQ: RXRX real-time stock quote data, in-depth charts, free RXRX options chain …That's what's happening with Recursion Pharmaceuticals (NASDAQ: RXRX), an innovative biotech. The company's shares are currently changing hands for $7.07 apiece, but the consensus one-year target ...Valence Labs, powered by Recursion, is redefining scientific discovery to radically improve lives. Following the acquisition of Valence Discovery by Recursion (NASDAQ: RXRX) in May 2023, Valence ...Nov 30, 2023 · Stock analysis for Recursion Pharmaceuticals Inc (RXRX:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. 20 Eyl 2022 ... (NASDAQ:RXRX). The stock is now deep in Busted IPO territory. Do the shares merit that fate or is something better ahead? An analysis ...NEW YORK, Dec. 10, 2021 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the results of the annual reconstitution of the Nasdaq Biotechnology Index (Nasdaq: NBI), which will become ...The Panera Bread Company is a public company that is traded on the NASDAQ stock market. The majority of its shareholders are financial institutions and mutual fund holders. The remaining shares are owned by direct holders of Panera Bread st...8 Eyl 2023 ... RSI Alert: Recursion Pharmaceuticals (RXRX) Now Oversold ... Legendary investor Warren Buffett advises to be fearful when others are greedy, and ...Jan 12, 2022 · So should Recursion Pharmaceuticals (NASDAQ:RXRX) shareholders be worried about its cash burn? In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of ... This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $35.00 ,the lowest forecast is $9.00. The …Average portfolio weight of all funds dedicated to RXRX is 0.48%, a decrease of 14.38%. Total shares owned by institutions decreased in the last three months by 7.71% to 130,292K shares.A lot of healthcare companies are seeking to brandish their AI bonafides, but Recursion Pharmaceuticals (RXRX 7.88%), and GE Healthcare Technologies (GEHC 1.39%) are already using AI to boost ...SALT LAKE CITY, May 08, 2023 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery, today reported ...12 Nis 2023 ... investments in companies including Recursion (NASDAQ: RXRX), which uses automation and deep learning to develop novel therapeutics; Enveda ...Industry. Biotechnology. No executives to display. Corporate headquarters. --, --. Find real-time RXRX - Recursion Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN ... Chief Business Officer (Nasdaq: RXRX). Recursion University of Cambridge. St Petersburg, Florida, United States. 3K followers 500+ connections. See your mutual ...Nov 24, 2023 · See the latest Recursion Pharmaceuticals Inc Class A stock price (RXRX:XNAS), related news, valuation, dividends and more to help you make your investing decisions. Webull offers RXRX Ent Holdg (RXRX) historical stock prices, in-depth market analysis, NASDAQ: RXRX real-time stock quote data, in-depth charts, free RXRX options chain data, and a fully built financial calendar to help you invest smart. Buy RXRX stock at Webull.Recursion Pharmaceuticals Inc (NASDAQ:RXRX) trade information. Sporting 7.88% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on Friday, 12/01/23 when the RXRX stock price touched $7.39 or saw a rise of 5.26%.SALT LAKE CITY, Dec. 6, 2021 /PRNewswire/ -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology to radically improve lives by industrializing drug discovery ...For a biotech like Recursion Pharmaceuticals (NASDAQ: RXRX) that aims to use artificial intelligence (AI) and petabytes of data as tools for drug discovery and development, computing power is a ...Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) was incorporated in 2013 and is headquartered in Salt Lake City, Utah. It operates as a clinical-stage biotechnology company, utilizing biology, ...SALT LAKE CITY, Aug. 18, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced that it ...24. Walkme Ltd (NASDAQ:WKME) SaaS company WalkMe is one of the stocks with negative beta. The company in August posted second quarter results. Adjusted EPS in the quarter came in at $0.00 beating ...Recursion Pharmaceuticals ( NASDAQ: RXRX) - the subject of this analysis - IPOd in April 2021, issuing 27.88m shares at a price of $18 per share, and raising >$500m - making it the sixth largest ...Recursion Pharmaceuticals (NASDAQ:RXRX) - the subject of this analysis - IPOd in April 2021, issuing 27.88m shares at a price of $18 per share, and raising >$500m - making it the sixth largest ...On October 25, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) announced that it has entered into a stock purchase agreement for the sale of approximately 15.3 million units of its common stock in a ...Nov 9, 2023 · About RecursionRecursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a ... Recursion Pharmaceuticals (NASDAQ:RXRX) stock popped in July, fueled by a game-changing development—a direct investment of $50 million from Nvidia. But, since that month’s peak, RXRX’s stock ...On July 21, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) reported that the European Commission has authorized an orphan drug designation to its inhibitor REC-4881 for the treatment of familial ...Nov 29, 2023 · 4 brokerages have issued twelve-month price objectives for Recursion Pharmaceuticals' stock. Their RXRX share price targets range from $8.00 to $15.00. On average, they anticipate the company's stock price to reach $11.20 in the next twelve months. This suggests a possible upside of 57.1% from the stock's current price. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Revenue Growth YOY: 291.46% Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a biotechnology company based in the United States.Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) institutional owners may be pleased with recent gains after 14% loss over the past year finance.yahoo.com - August 24 at 9:26 AM: Connor Clark & Lunn Investment Management Ltd. Buys 83,879 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) marketbeat.com - August 22 at 5:37 AMThe current price Recursion Pharmaceuticals ( RXRX) is trading at is $7.43, which is out of the analyst’s predicted range. Browse analyst ratings and price targets on …Nov 26, 2023 · NASDAQ: RXRX Recursion Pharmaceuticals. Market Cap. $2B. Today's Change (0.43%) $0.03. Current Price. $7.05. ... (RXRX 0.43%) that aims to use artificial intelligence (AI) and petabytes of data as ... Earnings for Recursion Pharmaceuticals are expected to decrease in the coming year, from ($1.67) to ($1.91) per share. Recursion Pharmaceuticals has not …Recursion Pharmaceuticals (NASDAQ:RXRX) was a new buy in the portfolio last week. This is a clinical-stage biotechnology company that combines experimental biology, bioinformatics, and artificial ...2013. 550. Chris Gibson. https://www.recursion.com. Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company …Recursion Pharmaceuticals Inc (NASDAQ: RXRX)’s stock price has increased by 1.33 compared to its previous closing price of 6.78. However, the company has seen a 3.00% increase in its stock price over the last five trading sessions. The Motley Fool reported 2023-11-26 that Nvidia will help Recursion build a massive supercomputer. This will be used […]Recursion Pharmaceuticals (NASDAQ: RXRX) stock popped in July, fueled by a game-changing development—a direct investment of $50 million from Nvidia. But, since that month’s peak, RXRX’s ...Recursion is forging key relationships with powerful collaborators. The young biotech's valuation is also looking a lot better now. However, its finances are nowhere near breakeven yet. NASDAQ: RXRX. Recursion Pharmaceuticals. Market Cap. $1B. Today's Change. (13.00%) $0.68.$6.92 0.14 [2.06%] Last update: 10:53AM (Delayed 15-Minutes) Get Real Time Here $6.85 -0.0700 [-1.01%] Profile News Analyst Ratings Guidance Dividends …Well, Nvidia (NASDAQ:NVDA) just invested $50 million to “boost Recursion’s drug-discovery companies.” Prior to today’s announcement, RXRX stock sat in negative territory for the year.Discovering new drugs is no easy task, and one young company that aims to help in that process is Recursion Pharmaceuticals (NASDAQ: RXRX). Though it still hasn't brought a product to market just ...Recursion Pharma (NASDAQ: RXRX) made waves this week.On Wednesday, the firm reported a hefty $50 million cash infusion from Nvidia to support efforts in developing AI models that speed up drug ...Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business updates and financial results for its third quarter ...Cathie Wood can't get enough of Recursion Pharmaceuticals (NASDAQ: RXRX) stock. Through her Ark Innovation ETF, the maverick growth stock portfolio manager bought shares of the biotech three times ...July 13, 2023 — 11:01 am EDT. Written by Zacks Equity Research for Zacks ->. Recursion Pharmaceuticals RXRX announced a significant investment worth $50 million from NVIDIA Corporation NVDA, a ...20 Eyl 2022 ... (NASDAQ:RXRX). The stock is now deep in Busted IPO territory. Do the shares merit that fate or is something better ahead? An analysis ...Recursion Pharmaceuticals (NASDAQ:RXRX) recently gapped higher after receiving a $50 million investment from AI powerhouse Nvidia (NASDAQ:NVDA).With that, Recursion will use NVDA technology to ...NASDAQ:RXRX. Stock Report. RXRX. Recursion Pharmaceuticals. Stock Analysis. Analyst Forecasts. ... RXRX Stock 12 Months Forecast. Average Price Target. $16.60 (124.63 ... RXRX U.S.: Nasdaq Recursion Pharmaceuticals Inc. Watch list Set a price target alert After Hours Last Updated: Dec 1, 2023 7:09 p.m. EST Delayed quote $ 7.44 0.05 0.68% After Hours Volume:... 12 Tem 2023 ... Confirming the ongoing fervor for all things artificial intelligence (AI), shares of biotechnology firm Recursion Pharmaceuticals (NASDAQ:RXRX) ...4. Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best and most notable AI healthcare stocks to buy. The Utah-based Recursion ...On October 11, 2023, Michael Secora, the Chief Financial Officer (CFO) of Recursion Pharmaceuticals Inc (NASDAQ:RXRX), sold 50,000 shares of the company.Feb 28, 2023 · Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.38 per share a year ago. Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.38 per share a year ago.Find the latest historical data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.15 Kas 2023 ... Graphic designer/iStock via Getty Images. AI-driven drug discovery firm Recursion Pharmaceuticals (NASDAQ:RXRX) added ~17% on Wednesday ...The average one-year price target for Recursion Pharmaceuticals Inc - (NASDAQ:RXRX) has been revised to 17.17 / share. This is an increase of 7.12% from the prior estimate of 16.03 dated August 31 ... Jul 13, 2023 · In recent trading, shares of Recursion Pharmaceuticals Inc (Symbol: RXRX) have crossed above the average analyst 12-month target price of $11.29, changing hands for $12.02/share. When a stock ... When the Nasdaq is said to be "down," that usually means that the Nasdaq Composite Index, an investment index comprised of some of the largest companies on the Nasdaq stock exchange, is losing value. This can be an indication that the broad...Find the latest news headlines from Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.2,015.20 +2.80(+0.14%) Advertisement Recursion Pharmaceuticals, Inc. (RXRX) NasdaqGS - NasdaqGS Real Time Price. Currency in USD Follow 2W 10W 9M 6.53 -0.33 (-4.81%) …Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) was incorporated in 2013 and is headquartered in Salt Lake City, Utah. It operates as a clinical-stage biotechnology company, utilizing biology, ...Mar 28, 2023 · Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Revenue Growth YOY: 291.46% Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a biotechnology company based in the United States. SALT LAKE CITY, May 25, 2021 /PRNewswire/ -- Recursion Pharmaceuticals, Inc. (Nasdaq : RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations ...Mar 28, 2023 · Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Revenue Growth YOY: 291.46% Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a biotechnology company based in the United States. View live Recursion Pharmaceuticals, Inc. chart to track its stock's price action. Find market predictions, RXRX financials and market news.2013. 550. Chris Gibson. https://www.recursion.com. Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company …A high-level overview of Recursion Pharmaceuticals, Inc. (RXRX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. A high-level overview of Recursion Pharmaceuticals, Inc. (RXRX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. RXRX: Recursion Pharmaceuticals Inc Stock Price Quote - NASDAQ GS - Bloomberg Subscribe S&P 500 4,556.62 +0.41% Nasdaq 14,265.86 +0.46% Crude Oil …SALT LAKE CITY, Aug. 18, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced that it ...SALT LAKE CITY, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its ...Recursion Pharmaceuticals (NASDAQ:RXRX) - the subject of this analysis - IPOd in April 2021, issuing 27.88m shares at a price of $18 per share, and raising >$500m - making it the sixth largest ...NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid-month and end-of-month settlement dates. It is then ... SALT LAKE CITY, June 13, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced the full ...SALT LAKE CITY, June 01, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation in ...Nov 16, 2023 · Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has been making great progress lately in being able to advance its pipeline. That's because it has been advancing two clinical candidates in phase 2 ... Salt Lake City, March 28, 2023 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery, today announced ...Fintel reports that on May 9, 2023, Needham reiterated coverage of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) with a Buy recommendation.. Analyst Price Forecast Suggests 206.61% Upside. As of ...Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel ...That’s as shares of Recursion Pharmaceuticals RXRX are exploding higher on the day. In fact, RXRX stock is currently up about 17% so far in the session. Butterfly with parabolic D leg action. This looks like classic D leg stuff. All parabolic action, few pullbacks and getting a lot of public attention. Microsoft Corporation Common Stock. $376.39 +0.22 +0.06%. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers ...The average twelve-month price prediction for Recursion Pharmaceuticals is $11.20 with a high price target of $15.00 and a low price target of $8.00. Learn more on RXRX's analyst rating history. Do Wall Street analysts like Recursion Pharmaceuticals more than its competitors?Microsoft Corporation Common Stock. $376.39 +0.22 +0.06%. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers ... Nasdaq rxrx

12 Tem 2023 ... buy RXRX Stock? or time to buy Nvidia Stock Price? A portion of this ... The Stock Market Will Finally Move (TOMORROW!) StockedUp New 6.4K .... Nasdaq rxrx

nasdaq rxrx

Nov 26, 2023 · NASDAQ: RXRX Recursion Pharmaceuticals. Market Cap. $2B. Today's Change (0.43%) $0.03. Current Price. $7.05. ... (RXRX 0.43%) that aims to use artificial intelligence (AI) and petabytes of data as ... Find the latest quotes for Vanguard S&P 500 ETF (VOO) as well as ETF details, charts and news at Nasdaq.com.Recursion Pharmaceuticals ( NASDAQ: RXRX) - the subject of this analysis - IPOd in April 2021, issuing 27.88m shares at a price of $18 per share, and raising >$500m - making it the sixth largest ...Recursion Pharmaceuticals Inc (NASDAQ: RXRX)’s stock price has increased by 1.33 compared to its previous closing price of 6.78. However, the company has seen a 3.00% increase in its stock price over the last five trading sessions. The Motley Fool reported 2023-11-26 that Nvidia will help Recursion build a massive supercomputer. This …Plus Therapeutics, Inc. (NASDAQ:PSTV) will present at the Conference on Brain Metastases, hosted by the Society for Neuro-Oncology, data from one planned clinical trial and one completed ...5 Eki 2023 ... The average one-year price target for Recursion Pharmaceuticals Inc - (NASDAQ:RXRX) has been revised to 17.17 / share.31 Eki 2023 ... Discovering new drugs is no easy task, and one young company that aims to help in that process is Recursion Pharmaceuticals (NASDAQ: RXRX).Find the latest quotes for Vanguard S&P 500 ETF (VOO) as well as ETF details, charts and news at Nasdaq.com.NASDAQ:RXRX. Stock Report. RXRX. Recursion Pharmaceuticals. Stock Analysis. Analyst Forecasts. ... RXRX Stock 12 Months Forecast. Average Price Target. $16.60 (124.63 ... Find the latest historical data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.Dec 4, 2023 · Recursion Pharmaceuticals Inc (NASDAQ: RXRX)’s stock price has gone decline by -0.34 in comparison to its previous close of 7.39, however, the company has experienced a 12.79% increase in its stock price over the last five trading days. The Motley Fool reported 2023-11-26 that Nvidia will help Recursion build a massive supercomputer. Price Target $11.20 Stock Analysis Analyst Forecasts Chart Competitors Earnings Financials Headlines Insider Trades Ownership SEC Filings Short Interest …Of the 22 guru strategies we follow, RXRX rates highest using our Value Investor model based on the published strategy of Benjamin Graham. This deep value methodology screens for stocks that have ...SALT LAKE CITY, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business ...Jul 12, 2023 · RXRX.O. Official Data Partner. Latest Trade. trading higher 7.14 USD. Change 0.12 % Change + 1.71% Positive ... Nasdaq leads Wall St to higher close as CPI report lifts sentiment July 12, 2023. Recursion Pharmaceuticals (NASDAQ:RXRX) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both small-cap medical companies, but which is the better stock?We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings, media sentiment, valuation and community ranking.View real-time RXRX stock price and news, along with industry-best analysis. ... Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet, Dow Jones. ETF Movers: Includes ETFs & ETNs with ...Of the 22 guru strategies we follow, RXRX rates highest using our Value Investor model based on the published strategy of Benjamin Graham. This deep value methodology screens for stocks that have ...24. Walkme Ltd (NASDAQ:WKME) SaaS company WalkMe is one of the stocks with negative beta. The company in August posted second quarter results. Adjusted EPS in the quarter came in at $0.00 beating ...Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...9 Kas 2023 ... ... (NASDAQ: RXRX), a leading clinical stage techbio company decoding biology to industrialize drug discovery. The two companies are working ...Plus Therapeutics, Inc. (NASDAQ:PSTV) will present at the Conference on Brain Metastases, hosted by the Society for Neuro-Oncology, data from one planned clinical trial and one completed ...Nov 29, 2023 · 4 brokerages have issued twelve-month price objectives for Recursion Pharmaceuticals' stock. Their RXRX share price targets range from $8.00 to $15.00. On average, they anticipate the company's stock price to reach $11.20 in the next twelve months. This suggests a possible upside of 57.1% from the stock's current price. RXRX Recursion Pharmaceuticals Inc Bayer and Recursion Focus Research Collaboration on Oncology. Berlin, Germany and Salt Lake City, USA, Nov. 09, 2023 (GLOBE NEWSWIRE) ...Track Recursion Pharmaceuticals Inc - Ordinary Shares - Class A (RXRX) Stock Price, Quote, latest community messages, chart, news and other stock related ...The average twelve-month price prediction for Recursion Pharmaceuticals is $11.20 with a high price target of $15.00 and a low price target of $8.00. Learn more on RXRX's analyst rating history. Do Wall Street analysts like Recursion Pharmaceuticals more than its competitors?Nov 29, 2023 · 4 brokerages have issued twelve-month price objectives for Recursion Pharmaceuticals' stock. Their RXRX share price targets range from $8.00 to $15.00. On average, they anticipate the company's stock price to reach $11.20 in the next twelve months. This suggests a possible upside of 57.1% from the stock's current price. Cathie Wood can't get enough of Recursion Pharmaceuticals (RXRX 7.88%) stock. Through her Ark Innovation ETF, the maverick growth stock portfolio manager bought shares of the biotech three times ...May 29, 2023 · On May 8, Recursion Pharmaceuticals (RXRX 7.88%) announced that it was going to buy a pair of AI-enabled drug discovery biotechs, Cyclica and Valence, for a total of $87.5 million -- paid in stock. Find the latest Earnings Report Date for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Add to Watchlist. Add to Portfolio. RXRX RXRX AFTER HOURS QUOTE RXRX LATEST AFTER HOURS TRADES. Based on analysts offering 12 month price targets for RXRX in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 .3 min read. ·. Jun 7, 2022. 2. Today we’re announcing the raise of two new Obvious funds, which combine to $461M of new capital: 4 We’ve completed the fundraise for our fourth flagship early ...Recursion Pharmaceuticals (NASDAQ:RXRX) stock popped in July, fueled by a game-changing development—a direct investment of $50 million from Nvidia. But, since that month’s peak, RXRX’s stock ...NASDAQ: RXRX · IEX Real-Time Price · USD. Add to Watchlist 6.96 +0.43 (6.58%) Nov 28, 2023, 3:34 PM EST - Market open. Overview; ... Stock Price Forecast. According to 6 stock analysts, the average 12-month stock price forecast for RXRX stock stock is $15.33, which predicts an increase of 120.26%. The lowest target is $8.00 and …SALT LAKE CITY, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery, today reported business updates and financial results for its fourth quarter and fiscal year ending December 31, 2022.Nov 22, 2023 · Nasdaq Composite Stock Market Premium Services. Stock Advisor. Our Flagship Service. Return. 524%. S&P Return. 133%. Rule Breakers. ... (RXRX 1.18%), an innovative biotech. The company's shares ... Jul 13, 2023 · In recent trading, shares of Recursion Pharmaceuticals Inc (Symbol: RXRX) have crossed above the average analyst 12-month target price of $11.29, changing hands for $12.02/share. When a stock ... Discovering new drugs is no easy task, and one young company that aims to help in that process is Recursion Pharmaceuticals (NASDAQ: RXRX). Though it still hasn't brought a product to market just ...Dec 2, 2023 · The latest price target for . Recursion Pharmaceuticals (NASDAQ: RXRX) was reported by JP Morgan on Monday, November 13, 2023.The analyst firm set a price target for 10.00 expecting RXRX to rise ... Recursion Pharmaceuticals (NASDAQ: RXRX) stock popped in July, fueled by a game-changing development—a direct investment of $50 million from Nvidia.But, since that month’s peak, RXRX’s stock ...At the time, Nvidia (NASDAQ:NVDA) had just investing $50 million in the company to help it create new AI models, and software to create new drug candidates. Since then, RXRX dropped to about $6 a ...Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio biotechnology company. It is focused on utilizing advanced technologies in biology, chemistry, …SALT LAKE CITY, Sept. 13, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced the initiation ...That's what's happening with Recursion Pharmaceuticals (NASDAQ: RXRX), an innovative biotech. The company's shares are currently changing hands for $7.07 apiece, but the consensus one-year target ...Recursion Pharmaceuticals Inc (NASDAQ: RXRX)’s stock price has increased by 1.33 compared to its previous closing price of 6.78. However, the company has seen a 3.00% increase in its stock price over the last five trading sessions. The Motley Fool reported 2023-11-26 that Nvidia will help Recursion build a massive supercomputer. This …Recursion Pharmaceuticals (NASDAQ: RXRX) has witnessed quite a roller-coaster year. A resounding investment of $50 million from tech titan Nvidia (NASDAQ: NVDA) in July rocketed its shares.The last time I mentioned Recursion Pharmaceuticals (NASDAQ:RXRX), it traded around $10.75 on Aug. 8.While the stock dipped to about $8.58 following that note, there’s still a lot to like here ...That’s as shares of Recursion Pharmaceuticals RXRX are exploding higher on the day. In fact, RXRX stock is currently up about 17% so far in the session. Butterfly with parabolic D leg action. This looks like classic D leg stuff. All parabolic action, few pullbacks and getting a lot of public attention. 2013. 550. Chris Gibson. https://www.recursion.com. Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in …. Agg bond